PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Sanigen saw its largest shareholder change to GC Partners in May 2026 and exited administrative-issue status in June 2026, easing some financial uncertainty, but it still faces eight consecutive years of losses alongside a fabricated-transaction loss issue.
On May 13, 2026, third-party allotment capital increase completed, changing the largest shareholder to GC Partners (45.5% stake) from the founder and affiliates
Exited KOSDAQ market-cap-deficiency administrative issue status effective June 29, 2026
A counterparty-driven fabricated transaction involving tungsten reagent products from 2023-2025 was confirmed, with 1.4 billion won booked as an illegal-act receivable
Revenue declined for four straight years from 26.8 billion won in 2022 to 15.4 billion won in 2025, with operating losses persisting throughout
Selected for the government's K-Hero program, securing roughly 3.58 billion won in funding for second-generation endolysin development, while pursuing new human diagnostics and microbiome businesses
Sanigen, headquartered in Anyang, Gyeonggi-do, is a food-safety diagnostics and control specialist positioning itself as a provider of a comprehensive 'Food Safety Total Solution' spanning microbial detection through sterilization and control.
Its main product lines include Genelix, a customized real-time PCR-based rapid microbial testing product; GeNext, a one-stop NGS panel for bulk sample processing; and Geneka, an NGS analysis service tailored to the food industry, supplemented by diagnostic consumables, sterilization products, and equipment sales.
The company's core underlying technology is a gene-marker discovery platform that identifies specific viruses and bacteria from vast microbial genetic databases, having secured European and Japanese patents for NGS panel technology detecting 16 bacterial species simultaneously and registering an African swine fever virus diagnostic kit with the World Organisation for Animal Health (WOAH) as the world's second such registration.
Its customer base spans the entire food industry value chain from production through distribution and consumption, with the company citing a total of 54 domestic and international patents and 27 awards and certifications.
Starting in 2026, the company has begun actively diversifying into high-value-added bio businesses by extending its food-safety technology into human diagnostics, microbiome-based healthcare, and second-generation endolysin development targeting antibiotic-resistant bacteria.
The endolysin project was selected as a research institution under the K-Hero cultivation and support program overseen by the Ministry of Science and ICT, receiving government funding over three years and six months through an industry-academia collaboration involving researchers from Seoul National University, Yonsei University, and Ewha Womans University, among others.
However, these new businesses remain at an early stage and have not yet translated into recorded revenue, and segment-level revenue breakdowns are not separately disclosed in the confirmed financial figures.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩8.6B | -₩800M | −9.2% |
| 2025Q3 | ₩4.1B | -₩900M | −22.4% |
| 2025Q4 | — | -₩1.8B | — |
| 2026Q1 | ₩3.3B | -₩900M | −26.3% |
| 2026Q2 | ₩3.8B | -₩400M | −10.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩26.8B | -₩4.1B | -₩4.1B | −15.3% | — | −221.0% |
| 2023 | ₩20.2B | -₩6.5B | -₩9.2B | −32.1% | −69.0% | 56.6% |
| 2024 | ₩15.4B | -₩5.9B | -₩6.6B | −38.1% | −79.6% | 78.2% |
| 2025 | ₩15.4B | -₩4.4B | -₩5.8B | −28.5% | −235.0% | 308.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Sanigen's revenue contracted for four consecutive years, from 26.76 billion won in 2022 to 20.19 billion won in 2023, 15.43 billion won in 2024, and 15.35 billion won in 2025.
Operating losses moved from 4.08 billion won in 2022 to 6.48 billion won in 2023, 5.87 billion won in 2024, and 4.37 billion won in 2025, showing the loss magnitude narrowing somewhat even as revenue shrank.
The operating margin stood at -32.1% in 2023, -38.1% in 2024, and -28.5% in 2025, indicating a modest improvement in the loss ratio relative to sales though still deeply negative.
Net income attributable to owners remained negative across all four years at -4.06 billion won in 2022, -9.25 billion won in 2023, -6.56 billion won in 2024, and -5.82 billion won in 2025, with the large 2023 loss likely reflecting one-off listing-related expenses.
On a quarterly basis, the fourth quarter of 2025 saw operating loss widen sharply to 1.78 billion won with a net loss of 3.17 billion won, a result understood to reflect one-off factors including the recognition of losses from the tungsten reagent fabricated transaction.
Entering 2026, revenue showed modest recovery with operating losses narrowing, at 3.31 billion won revenue and 0.87 billion won operating loss in the first quarter and 3.81 billion won revenue and 0.41 billion won operating loss in the second quarter.
Notably, the second-quarter 2026 net loss attributable to owners shrank sharply to 0.15 billion won from 0.90 billion won in the prior quarter, a development interpreted as reflecting improved capital structure following the equity raise alongside the fading of one-off losses.
Operating cash flow remained negative across all four years (-3.21 billion won in 2022, -3.78 billion won in 2023, -5.44 billion won in 2024, -4.18 billion won in 2025), and a recovery in cash generation from core operations has yet to be confirmed.
The food-safety diagnostics industry serves steady demand for microbial and pathogen detection and hygiene management across the entire food manufacturing and distribution chain, with competition from large domestic and global diagnostics equipment and service providers alongside a range of smaller specialized firms.
Sanigen has sought a differentiated position by offering an integrated diagnostics (real-time PCR, NGS) and control (sterilization) solution, though the four-year decline in revenue may relate to intensifying competition or the loss of major customers within the sector.
Media reports have indeed noted that the company experienced the departure of a major client and turnover within its R&D organization.
Meanwhile, the human molecular diagnostics, microbiome healthcare, and next-generation antimicrobial (endolysin) markets the company has announced entry into align with global trends toward precision medicine and combating antibiotic-resistant bacteria, areas viewed as having growth potential, though numerous domestic and international bio and diagnostics firms are already competing to establish positions there, making differentiation as a new entrant a key question.
Achievements such as the WOAH registration of its African swine fever virus diagnostic kit are cited as evidence of technical capability, but how much this has translated into actual revenue is not confirmed by publicly disclosed segment-level data.
Several other KOSDAQ-listed companies have faced similar administrative-issue designation risk due to market-cap deficiency, a pattern cited as illustrating the structural vulnerability of smaller technology-special-listed companies.
In April 2026, Sanigen's board decided on a roughly 10 billion won third-party allotment capital increase targeting GC Partners, disclosing that proceeds would be allocated to 3.5 billion won for bio-industry R&D, 2.5 billion won for global export expansion infrastructure, 3.1 billion won for operating expenses, and 0.9 billion won for debt repayment.
Upon completion of the payment on May 13, 2026, the largest shareholder changed from the founder and seven affiliates (previously 18.05%) to GC Partners (45.5%), with the company stating that new executive appointments were planned to follow.
The company exited KOSDAQ market-cap-deficiency administrative-issue status effective June 29, 2026, removing one factor that had weighed on investor sentiment.
Building on this improved capital structure, the company has stated plans to direct R&D resources toward high-value-added bio businesses including human molecular diagnostics, microbiome-based healthcare, and second-generation endolysin development, though the timing and scale of any revenue contribution from these businesses have not yet been officially specified.
Regarding the fabricated-transaction loss related to tungsten reagent products (1.4 billion won booked as an illegal-act receivable), the company has maintained it was a victim of fraud and stated it has filed criminal complaints against those involved, and explained that it received an unqualified audit opinion after improving internal accounting controls and restating its audit report.
However, the ultimate recoverability of this matter and the possibility of further losses remain items requiring confirmation through future disclosures.
Given Sanigen's multi-year history of operating and net losses, conventional profit-based valuation metrics are difficult to apply.
From a price-to-book perspective, the stock trades at a premium to net asset value, suggesting the market is weighing the potential of the business restructuring and new bio ventures following the ownership change more heavily than current financial performance.
Dividend appeal is limited given no payout track record in recent years. The large third-party allotment capital increase in May 2026 expanded the share count, a factor that warrants consideration of dilution effects in future per-share metric calculations.
Given the company's continued-loss profile, the pace of balance-sheet improvement and whether new businesses translate into revenue are likely to matter more to market assessment than traditional earnings-multiple comparisons.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
A roughly 10 billion won third-party allotment capital increase targeting GC Partners was completed in May 2026, lowering the debt ratio and bolstering operating funds. A significant portion of these funds was allocated to bio-industry R&D and global export infrastructure, creating room for new business investment. The administrative-issue designation was also lifted, resolving some listing-related uncertainty.
The company is pursuing new businesses extending its food-safety technology into human applications, including molecular diagnostics, microbiome healthcare, and second-generation endolysin development.
The endolysin project secured government funding over three years and six months through selection for the K-Hero program and features an industry-academia collaboration structure with researchers from major universities.
Existing technical achievements, such as the world's second WOAH registration of its African swine fever diagnostic kit, could serve as a foundation for new business expansion.
The operating margin improved from -38.1% in 2024 to -28.5% in 2025, and the ratio of operating loss to revenue continued to ease in both the first and second quarters of 2026. Net loss attributable to owners in the second quarter of 2026 fell sharply to 0.15 billion won from 0.90 billion won in the prior quarter.
The improved capital structure following the equity raise is understood to have contributed in part to the narrower net loss.
Sanigen has not posted an annual profit even once since 2018, and revenue declined for four straight years from 26.76 billion won in 2022 to 15.35 billion won in 2025. Operating cash flow was also negative in all four years, indicating that cash generation from core operations has yet to recover.
Whether the pivot to new businesses can offset the structural weakness in the core business remains unconfirmed.
A fraudulent fabricated transaction perpetrated by a counterparty in tungsten reagent product trading from 2023 to 2025 was discovered, leading to a 1.4 billion won illegal-act receivable being booked, an amount equivalent to 57% of shareholders' equity.
The fact that this went undetected for three years suggests structural gaps in transaction verification and inventory confirmation procedures, weighing on credibility. The company has filed criminal complaints, but recoverability remains uncertain.
The third-party allotment capital increase gave new largest shareholder GC Partners a 45.5% stake, substantially diluting existing shareholders.
With new executive appointments planned, the future business direction may shift from the existing food-safety business toward new bio ventures, leaving uncertainty around strategic continuity and execution during this transition.
Media reports have also noted compounding negative factors including the departure of a major client and turnover in R&D personnel.
The debt ratio reached 308.3% at the end of 2025, with four consecutive years of net losses eroding total equity. While the capital increase brought temporary improvement, the structure remains highly dependent on continued external funding.
Additional capital increases or convertible bond issuances could result in further dilution for existing shareholders.
The fabricated transaction incident involving tungsten reagent products led to financial statement restatement, exposing structural weaknesses in the company's transaction verification and internal accounting control systems.
A recurrence of similar issues could place additional pressure on audit opinions or market confidence. Whether the 1.4 billion won illegal-act receivable will ultimately be recovered remains uncertain.
New businesses such as human molecular diagnostics, microbiome healthcare, and endolysin development remain pre-revenue, and development delays, clinical or regulatory approval issues, or intensified competition could prevent planned outcomes from materializing.
Integration risk with the existing organization also exists during the transition to new management. Whether the company can sustain R&D with its own funding after government support programs end also warrants observation.
Check whether the third-quarter 2026 revenue and operating loss trend continues the loss-narrowing pattern seen in the first two quarters, and whether any revenue recognition from new businesses has begun.
Check for concrete details on new executive appointments and the direction of business restructuring led by GC Partners, including new officer lineups and reorganization of new business units.
Check the progress of recovery efforts for the 1.4 billion won illegal-act receivable related to the tungsten reagent fabricated transaction, and the outcome of associated criminal proceedings.
Check for interim result announcements from the government-supported R&D project and whether candidate substances have been identified.
Sanigen passed through two major inflection points in the first half of 2026—a change in largest shareholder and exit from administrative-issue status—resolving some financial uncertainty, yet its core food-safety diagnostics business has seen revenue contract for a fourth straight year, and the eight-year loss streak continues.
While operating and net losses narrowed in the first and second quarters of 2026, this is understood to reflect a combination of improved capital structure from the equity raise and the fading of one-off losses, making it premature to conclude the core business has recovered.
The tungsten reagent fabricated transaction incident exposed structural weaknesses in internal controls even as the company maintains a victim stance, and the ultimate recoverability of the related receivable remains uncertain.
The company has announced a pivot toward high-value-added bio businesses including human molecular diagnostics, microbiome healthcare, and second-generation endolysin development, and while an initial foundation has been established through selection for government support programs, the timing and scale of any actual revenue conversion remain unconfirmed.
With new executive appointments and business restructuring planned under the new GC Partners-led ownership structure, organizational integration and execution capability will be key points to observe going forward.
Investors will want to watch, in balanced fashion, the durability of the balance sheet improvement, whether new businesses convert into revenue, and whether risks tied to the fabricated transaction are resolved.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.